World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
62
Citations
14274
World Ranking
3137
National Ranking
120

Overview

Josée Golay is affiliated with the Mario Negri Institute for Pharmacological Research in Italy. Their research spans several interconnected fields, primarily focusing on medicine, biochemistry, genetics, and molecular biology. The researcher has contributed extensively to oncology, genetics, immunology, molecular biology, and radiology through a variety of scientific studies.

The main areas of research conducted by Josée Golay include:

  • CAR-T cell therapy research
  • Monoclonal and Polyclonal Antibodies Research
  • Virus-based gene therapy research
  • Chronic Lymphocytic Leukemia Research
  • Immune Cell Function and Interaction
  • Mesenchymal stem cell research
  • Glycosylation and Glycoproteins Research

Notable recent publications by Josée Golay feature several key topics related to antibodies and cell therapy. These include:

  • The Role of Complement in the Mechanism of Action of Therapeutic Anti-Cancer mAbs, 2020, Antibodies
  • Role of Fc Core Fucosylation in the Effector Function of IgG1 Antibodies, 2022, Frontiers in Immunology

Josée Golay regularly publishes in high-impact venues, with frequent contributions to:

  • Antibodies
  • Frontiers in Immunology
  • Cytotherapy
  • Blood
  • Blood Cancer Journal

The researcher often collaborates with a set of frequent coauthors, including:

  • Martino Introna
  • Alessandro Rambaldi
  • Chiara Capelli
  • Irene Cattaneo
  • Elisa Gotti

Josée Golay's research contributions focus notably on advancing understanding and therapeutic applications in immunology and oncology. Their work on CAR-T cells, monoclonal antibodies, and glycosylation processes addresses key mechanisms relevant to cancer treatment and immune modulation.

Best Publications

  • Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis

    Josée Golay;Luisella Zaffaroni;Thomas Vaccari;Thomas Vaccari;Manuela Lazzari;Manuela Lazzari

  • Complement Activation Determines the Therapeutic Activity of Rituximab In Vivo

    Nicola Di Gaetano;Elena Cittera;Rachele Nota;Annunciata Vecchi

  • From the bench to the bedside: ways to improve rituximab efficacy

    Guillaume Cartron;Hervé Watier;Josée Golay;Philippe Solal-Celigny

  • Interleukin-1-inducible genes in endothelial cells. Cloning of a new gene related to C-reactive protein and serum amyloid P component.

    F Breviario;E M d'Aniello;J Golay;G Peri

  • CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59

    Josée Golay;Manuela Lazzari;Valeria Facchinetti;Sergio Bernasconi

  • The toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells.

    Emer Bourke;Daniela Bosisio;Josée Golay;Nadia Polentarutti

  • Dual-functional capability of CD3 +CD56 + CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity

    Alice Pievani;Gianmaria Borleri;Daniela Pende;Lorenzo Moretta

  • Inducible expression of PTX3, a new member of the pentraxin family, in human mononuclear phagocytes

    Victor Vidai Alles;Barbara Bottazzi;Giuseppe Peri;Josée Golay

  • Autologous Mesenchymal Stromal Cells and Kidney Transplantation: A Pilot Study of Safety and Clinical Feasibility

    Norberto Perico;Federica Casiraghi;Martino Introna;Eliana Gotti

  • M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro

    Marzia Leidi;Elisa Gotti;Luca Bologna;Elena Miranda

  • Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab.

    Josée Golay;Fabio Da Roit;Luca Bologna;Claudia Ferrara

  • Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone

    N. Di Gaetano;Y. Xiao;E. Erba;R. Bassan

  • Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study

    Martino Introna;Gianmaria Borleri;Elena Conti;Marta Franceschetti

  • Treatment of graft versus host disease with mesenchymal stromal cells: a phase I study on 40 adult and pediatric patients.

    Martino Introna;Giovanna Lucchini;Erica Dander;Stefania Galimberti

  • Mechanism of Action of Type II, Glycoengineered, Anti-CD20 Monoclonal Antibody GA101 in B-Chronic Lymphocytic Leukemia Whole Blood Assays in Comparison with Rituximab and Alemtuzumab

    Luca Bologna;Elisa Gotti;Massimiliano Manganini;Alessandro Rambaldi

  • The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle.

    J. T. Golay;E. A. Clark;P. C. L. Beverley

  • Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft-versus-host disease in a pediatric population.

    Giovanna Lucchini;Martino Introna;Erica Dander;Attilio Rovelli

  • Genetic modification of human T cells with CD20 : A strategy to purify and lyse transduced cells with anti-CD20 antibodies

    Martino Introna;Anna M. Barbui;Federica Bambacioni;Chiara Casati

  • Human platelet lysate allows expansion and clinical grade production of mesenchymal stromal cells from small samples of bone marrow aspirates or marrow filter washouts.

    C Capelli;M Domenghini;G Borleri;P Bellavita

  • Cytokine-induced killer cells are terminallydifferentiated activated CD8 cytotoxic T-EMRA lymphocytes

    Marta Franceschetti;Alice Pievani;Gianmaria Borleri;Luca Vago

Frequent Co-Authors

Martino Introna
Martino Introna Mario Negri Institute for Pharmacological Research
Alessandro Rambaldi
Alessandro Rambaldi University of Milan
Andrea Biondi
Andrea Biondi University of Milano-Bicocca
Tiziano Barbui
Tiziano Barbui FROM-Fondazione per la Ricerca Ospedale di Bergamo
Alberto Mantovani
Alberto Mantovani Humanitas University
Giovanni Cazzaniga
Giovanni Cazzaniga University of Milano-Bicocca
Giuseppe Peri
Giuseppe Peri Mario Negri Institute for Pharmacological Research
Guido Finazzi
Guido Finazzi Mario Negri Institute for Pharmacological Research
Antonino Neri
Antonino Neri University of Milan
Francesco Colotta
Francesco Colotta Mario Negri Institute for Pharmacological Research

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a degree in Immunology opens diverse career paths in healthcare and research. For those interested in clinical applications, exploring online accelerated nursing programs for non nurses can provide an efficient route into nursing, even without a prior healthcare background.

If you’re aiming to quickly enter the nursing profession, consider options like accelerated nursing programs. These programs are designed to build your clinical knowledge fast and prepare you for roles in hospitals or research settings.

For those interested in foundational nursing roles, exploring easy lpn programs to get into can be a practical starting point. Licensed Practical Nurse qualifications help build valuable patient care skills that complement immunological studies.

Advancing further, becoming a Nurse Practitioner is another promising pathway. Many students benefit from choosing easy nurse practitioner programs to get into that balance accessibility with strong clinical training, leading to impactful roles in primary care and disease management.

Best Scientists Citing Josée Golay

Trending Scientists

Recently Published Articles